The choice of hematopoietic progenitor cell source for transplantation is determined by multiple factors including the underlying disease (hematologic malignancy vs non-malignant hematologic disorder), conditioning regimen (myeloablative vs reduced intensity), and type of donor. Data from the prospective randomized Blood and Marrow Transplant Clinical Trial Network 0201 trial regarding bone marrow versus peripheral blood stem cell for hematopoietic cell transplantation, the declining quality of bone marrow harvests over the past two decades, and improved prevention of chronic graft versus host disease will be addressed in this context. This presentation will also address quality improvement strategies for the collection of bone marrow and innovative approaches for optimizing progenitor cell collections by apheresis, including the use of novel agents such as plerixafor and chemokine ligand 2 (CXCL2), to enhance progenitor cell yield and maximize donor safety.
To view Spanish or English subtitles, click the "CC" box in the video player. Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Describe the outcomes of the Blood and Marrow Transplant Clinical Trials Network 0201 trial
Discuss strategies for improving the quality of bone marrow harvests
Describe innovative approaches for optimizing the collection of hematopoietic progenitor cells by apheresis
Moderator & Speaker(s):
Massachusetts General Hospital & Harvard Medical School
All relevant financial relationships have been mitigated. By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
AM21-39: Optimization of Progenitor Cell Sources for Hematopoetic Cell Transplantation Evaluation